BiCNU (carmustine for injection) is indicated in established combination therapy with other approved chemotherapeutic agents in the following: Glioblastoma; Hodgkin's lymphoma - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy; Non-Hodgkin's lymphoma - as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.